{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:50:20Z","timestamp":1778953820001,"version":"3.51.4"},"reference-count":41,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.1080\/13696998.2022.2059220","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:32:40Z","timestamp":1648625560000},"page":"491-502","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective"],"prefix":"10.1080","volume":"25","author":[{"given":"Katja C.","family":"Heinz","sequence":"first","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8263-4047","authenticated-orcid":false,"given":"Damon","family":"Willems","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.08.031"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401"},{"key":"e_1_3_3_4_1","unstructured":"Avail Dermatology. Top 5 Most Common Skin Conditions. 2018. [cited 2021 Jun 10]. Available from: https:\/\/availdermatology.com\/common-skin-conditions\/."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511545771"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.09.076"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.02.025"},{"key":"e_1_3_3_8_1","volume-title":"Atopic dermatitis\/atopic eczema: disease landscape & forecast","author":"Love I","year":"2020","unstructured":"Love I, White K. Atopic dermatitis\/atopic eczema: disease landscape & forecast. Decision Resources Group. 2020."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13084"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3212"},{"issue":"10","key":"e_1_3_3_12_1","first-page":"590","article-title":"Atopic dermatitis: diagnosis and treatment","volume":"101","author":"Frazier W","year":"2020","unstructured":"Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590\u2013598.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_3_3_14_1","unstructured":"National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis: Technology appraisal guidance [TA534]. 2018. [cited 2021 Jun 10]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA534."},{"key":"e_1_3_3_15_1","unstructured":"European Medicines Agency. Rinvoq: upadacitinib. 2021. [cited 2021 Dec 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq."},{"key":"e_1_3_3_16_1","unstructured":"Medicines and Healthcare products Regulatory Agency. SUMMARY OF PRODUCT CHARACTERISTICS. 2021. [cited 2021 Oct 23]. Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/9890d20041d9d6b42d1d098c89bfe58333260ad7."},{"key":"e_1_3_3_17_1","unstructured":"National Institute for Health and Care Excellence. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]: In development [GID-TA10597]. 2021. [cited 2021 Jun 10]. Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10597."},{"key":"e_1_3_3_18_1","unstructured":"European Medicines Agency. Cibinqo: abrocitinib. 2021. [cited 2021 Dec 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cibinqo."},{"key":"e_1_3_3_19_1","unstructured":"National Institute for Health and Care Excellence. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]: In development [GID-TA10596]. 2021. [cited 2021 Jun 28]. Available from: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10596."},{"key":"e_1_3_3_20_1","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"2015","unstructured":"Drummond MF, Sculpher M, Claxton K, et\u00a0al. Methods for the economic evaluation of health care programmes. 4th edn. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0033"},{"key":"e_1_3_3_22_1","volume-title":"Systematic reviews to answer health care questions","author":"Nelson HD.","year":"2014","unstructured":"Nelson HD. Systematic reviews to answer health care questions. Philadelphia: Wolters Kluwer Health; 2014."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_3_24_1","unstructured":"Institute for clinical and economic review. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value. 2017. [cited 2021 Jul 4]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/MWCEPAC_ATOPIC_EVIDENCE_REPORT_051217.pdf."},{"key":"e_1_3_3_25_1","unstructured":"National Institute for Health and Care Excellence. Baricitinib for treating moderate to severe atopic dermatitis: technology appraisal guidance [TA681]. 2021. [cited 2021 Jun 10]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta681."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2013.01.017"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3023"},{"key":"e_1_3_3_33_1","unstructured":"Office for National Statistics. National life tables: UK. 2021. [cited 2021 May 6]. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables."},{"key":"e_1_3_3_34_1","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. [cited 2021 Jun 10]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"key":"e_1_3_3_35_1","unstructured":"Curtis L Burns A. Unit Costs of Health and Social Care 2019 | PSSRU. 2019. [cited 2021 Jun 6]. Available from: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2019\/."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.002"},{"key":"e_1_3_3_37_1","unstructured":"National Institute for Health and Care Excellence. BNF British National Formulary. 2021. [cited 2021 May 6]. Available from: https:\/\/bnf.nice.org.uk\/"},{"key":"e_1_3_3_38_1","unstructured":"National Health Service. National tariff payment system documents annexes and supporting documents. 2020. [cited 2021 Jun 10]. Available from: https:\/\/www.england.nhs.uk\/publication\/national-tariff-payment-system-documents-annexes-and-supporting-documents\/"},{"key":"e_1_3_3_39_1","unstructured":"National Health Service. National cost collection for the NHS. 2019. [cited 2021 Jun 10]. Available from: https:\/\/www.england.nhs.uk\/national-cost-collection\/"},{"key":"e_1_3_3_40_1","unstructured":"Institute for clinical and economic review. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value. 2021. [cited 2021 Jul 4]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/12\/ICER_Atopic-Dermatitis_Draft-Evidence-Report_051421.pdf"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454579"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19457"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2022.2059220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:26:19Z","timestamp":1729164379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2022.2059220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,31]]}},"alternative-id":["10.1080\/13696998.2022.2059220"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2022.2059220","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}